Methotrexate treatment of FraX fibroblasts results in FMR1 transcription but not in detectable FMR1 protein levels

BACKGROUND: Fragile X syndrome is caused by the loss of FMRP expression due to methylation of the FMR1 promoter. Treatment of fragile X syndrome patients’ lymphoblastoid cells with 5-azadeoxycytidine results in demethylation of the promoter and reactivation of the gene. The aim of the study was to a...

Descripción completa

Detalles Bibliográficos
Autores principales: Brendel, Cornelia, Mielke, Benjamin, Hillebrand, Merle, Gärtner, Jutta, Huppke, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2013
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846751/
https://www.ncbi.nlm.nih.gov/pubmed/24020679
http://dx.doi.org/10.1186/1866-1955-5-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3846751/
https://www.ncbi.nlm.nih.gov/pubmed/24020679
http://dx.doi.org/10.1186/1866-1955-5-23

Ejemplares similares